Relapsed Diffuse Large B-Cell Lymphoma: Clinical Utility of Cell of Origin

被引：5

作者：

Vose, Julie M. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Omaha, NE 68198 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 31期

关键词：

TISSUE MICROARRAY; GERMINAL CENTER; SURVIVAL; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY; RITUXIMAB; SUBTYPES; IMPROVES;

D O I：

10.1200/JCO.2011.37.5733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4065 / 4066

页数：2

共 50 条

[1] Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation
Gu, Keni
Weisenburger, Dennis D.
Fu, Kai
Chan, Wing C.
Greiner, Timothy C.
Aoun, Patricia
Smith, Lynette M.
Bast, Martin
Liu, Zhongfen
Bociek, R. Gregory
Bierman, Philip J.
Armitage, James O.
Vose, Julie M.
HEMATOLOGICAL ONCOLOGY, 2012, 30 (03) : 143 - 149
[2] Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Desai, Sanjal H.
Mwangi, Raphael
Smith, Alexandra N.
Maurer, Matthew J.
Farooq, Umar
King, Rebecca L.
Cerhan, James R.
Feldman, Andrew L.
Habermann, Thomas M.
Thompson, Carrie A.
Wang, Yucai
Ansell, Stephen M.
Witzig, Thomas E.
Nowakowski, Grzegorz S.
HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 39 - 49
[3] Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma
Balague, O.
Campo, E.
ANNALS OF ONCOLOGY, 2017, 28 (05) : 918 - 920
[4] Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma
Iqbal, Madiha
Castano, Yennifer Gil
Paludo, Jonas
Rosenthal, Allison
Li, Zhuo
Beltran, Manuel
Moustafa, Muhamad Alhaj
Inwards, David
Porrata, Luis
Micallef, Ivana
Bisneto, Jose C. Villasboas
Johnston, Patrick
Ansell, Stephen M.
Reeder, Craig
Murthy, Hemant
Roy, Vivek
Foran, James
Tun, Han W.
Kharfan-Dabaja, Mohamed A.
Ayala, Ernesto
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02) : E89 - E95
[5] Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Bartlett, Nancy L.
Hahn, Uwe
Kim, Won-Seog
Fleury, Isabelle
Laribi, Kamel
Bergua, Juan-Miguel
Bouabdallah, Krimo
Forward, Nicholas
Bijou, Fontanet
Macdonald, David
Portell, Craig A.
Ghesquieres, Herve
Nowakowski, Grzegorz
Yasenchak, Christopher A.
Patterson, Monica
Ho, Linda
Rustia, Evelyn
Fanale, Michelle
Jie, Fei
Kim, Jeong-A
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09) : 1061 - 1072
[6] Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
Rampotas, Alexandros
Sangha, Gina
Collins, Graham P.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[7] Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Meyer, Paul N.
Fu, Kai
Greiner, Timothy C.
Smith, Lynette M.
Delabie, Jan
Gascoyne, Randy D.
Ott, German
Rosenwald, Andreas
Braziel, Rita M.
Campo, Elias
Vose, Julie M.
Lenz, Georg
Staudt, Louis M.
Chan, Wing C.
Weisenburger, Dennis D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 200 - 207
[8] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Furqan, Fateeha
Hamadani, Mehdi
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[9] Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Nijland, Marcel
Seitz, Annika
Terpstra, Martijn
van Imhoff, Gustaaf W.
Kluin, Philip M.
van Meerten, Tom
Atayar, Cigdem
van Kempen, Leon C.
Diepstra, Arjan
Kok, Klaas
van den Berg, Anke
CANCERS, 2018, 10 (11):
[10] Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma
Hill, Brian T.
Sweetenham, John
LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 763 - 769

← 1 2 3 4 5 →